Blood Coagulation Factors And Fibrin, E.g., Thromboplastin, Etc. Patents (Class 530/381)
-
Publication number: 20100323421Abstract: It is an object of the present invention to provide a method for chemically modifying biopolymer and polypeptide with a hydrophobic compound or a compound which causes degradation or reaction under basic condition. The present invention provides a method for producing a chemically modified biopolymer or polypeptide, wherein a biopolymer or polypeptide is chemically modified in a reaction solution containing an organic fluorine compound.Type: ApplicationFiled: November 28, 2008Publication date: December 23, 2010Applicant: FUJIFILM CorporationInventors: Shouji Ooya, Tetsuo Hiratou, Kentaro Nakamura
-
Publication number: 20100324114Abstract: The present invention relates to a method of diagnosing hereditary angioedema type III (HAE III) or a predisposition thereto in a subject being suspected of having developed or of having a predisposition to develop a hereditary angioedema type III or in a subject being suspected of being a carrier for hereditary angioedema type III, the method comprising determining in vitro from a biological sample of said subject the presence or absence of a disease-associated mutation in a nucleic acid molecule regulating the expression of or encoding coagulation factor XII; wherein the presence of such a mutation is indicative of a hereditary angioedema type III or a predisposition thereto.Type: ApplicationFiled: October 3, 2008Publication date: December 23, 2010Inventor: Georg Dewald
-
Publication number: 20100317585Abstract: Polypeptides and polynucleotides encoding same comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotrophin attached to a carboxy terminus of a coagulation factor and not to an amino terminus are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using same are also disclosed.Type: ApplicationFiled: June 30, 2010Publication date: December 16, 2010Inventors: Udi Eyal Fima, Gili Hart
-
Publication number: 20100260706Abstract: The present invention relates to biologically active polypeptides linked to one or more accessory polypeptides. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.Type: ApplicationFiled: December 23, 2009Publication date: October 14, 2010Inventors: Oren Bogin, Willem P. Stemmer, Volker Schellenberger, Yong Yin, Chia-wei Wang, Nathan C. Geething
-
Patent number: 7803911Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.Type: GrantFiled: February 13, 2009Date of Patent: September 28, 2010Assignee: Quandrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7790680Abstract: The invention relates to a stable solid pharmaceutical composition comprising factor VIII. Such a composition is devoid of amino acids and comprises: (a) factor VIII; (b) a surfactant; (c) calcium chloride; (d) sucrose; (e) sodium chloride; (f) trisodium citrate; and (g) a buffer devoid of amino acids; and has a pH from 6 to 8 prior to lyophilization and after reconstitution in water for injection. The invention also relates to the liquid pharmaceutical composition obtainable after dilution of said stable solid pharmaceutical composition with sterile water optionally containing sodium chloride.Type: GrantFiled: March 26, 2003Date of Patent: September 7, 2010Assignee: Ipsen Pharma S.A.S.Inventors: Mary White, Paul Webb
-
Publication number: 20100222554Abstract: The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. I.e., the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide.Type: ApplicationFiled: April 2, 2007Publication date: September 2, 2010Inventors: Thomas Weimer, Hubert Metzner, Stefan Schulte, Wiegand Lang, Wilfried Wormsbächer
-
Publication number: 20100210821Abstract: A process for isolation and purification of a target protein by chromatography wherein the chromatography removes or depletes prions (PrPSC), comprising the steps of contacting a potentially PrPSC contaminated sample comprising a target protein with a multimodal chromatographic material; setting buffer conditions so that the target protein is bound to the multimodal chromatographic material and whereas PrPSC is not binding to the multimodal chromatographic material; followed by elution of the target protein. a process for isolation and purification of a target protein free of prion protein (prpSC).Type: ApplicationFiled: August 25, 2008Publication date: August 19, 2010Inventors: Gustav Gilljam, Mats Jernberg, Stefan Winge, Andrea Neisser-Svae
-
Patent number: 7772371Abstract: The activated coagulation Factor X (FXa) stimulating agents may be used in the treatment of hemorrhages in a subject. Compounds and combinations are described which are particularly useful for the topical treatment of hemorrhaging in healthy subjects or in patients with hemorrhagic diathesis.Type: GrantFiled: August 3, 2006Date of Patent: August 10, 2010Assignee: Thrombotargets CorporationInventors: Javier Pedreño Egea, Luis Caveda Catasús
-
Publication number: 20100183589Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: March 31, 2010Publication date: July 22, 2010Applicant: VENTRIA BIOSCIENCEInventors: Ning Huang, Raymond L. Rodriguez, Frank E. Hagie, David M. Stalker
-
Publication number: 20100166700Abstract: The present invention relates to polymeric reagents and conjugates thereof, methods for synthesizing the polymeric reagents and conjugates, pharmaceutical compositions comprising the conjugates and methods of using the polymer conjugates including therapeutic methods where conjugates are administered to patients.Type: ApplicationFiled: February 28, 2007Publication date: July 1, 2010Applicant: OLIGASIS CORPORATIONInventor: Stephen A. Charles
-
Publication number: 20100159465Abstract: The present invention relates techniques for identifying suitable secretion fusion partner (SFP) for hyper-secretory production of recombinant proteins. The SFPs can be obtained from secretome analyses. Recombinant proteins are produced in a fusion form with a secretion fusion partner (SFP) and can be separated from the SFP by in vitro protease treatment. SFPs of this invention greatly improve the secretion level of target proteins and peptides which are valuable for bio-pharmaceuticals and the bio-industry.Type: ApplicationFiled: December 4, 2009Publication date: June 24, 2010Inventors: JUNG-HOON SOHN, JUNG-HOON BAE, HYUN-JIN KIM, KWANG-MOOK LIM, SEUNG LI KIM
-
Publication number: 20100145020Abstract: It is an object of the present invention to obtain a soluble thrombomodulin substantially not containing a denatured product of soluble thrombomodulin that may be generated under acidic conditions.Type: ApplicationFiled: March 21, 2008Publication date: June 10, 2010Applicant: Asahi Kasei Pharma CorporationInventor: Susumu Ohigashi
-
Publication number: 20100144601Abstract: A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, preferably human Tenascin, that binds to human TNF? including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.Type: ApplicationFiled: October 27, 2009Publication date: June 10, 2010Inventors: Steven Jacobs, Karyn O'Neil
-
Publication number: 20100137511Abstract: Conjugates of a Factor IX moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided (among other things) are compositions comprising the conjugates, methods of making the conjugates, and methods of administering to a patient compositions comprising the conjugates.Type: ApplicationFiled: December 15, 2009Publication date: June 3, 2010Applicant: Nektar TherapeuticsInventors: Mary J. Bossard, Gayle Stephenson
-
Publication number: 20100121034Abstract: The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs.Type: ApplicationFiled: January 15, 2010Publication date: May 13, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20100120664Abstract: The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences.Type: ApplicationFiled: December 21, 2007Publication date: May 13, 2010Inventors: Stefan Schulte, Thomas Weimer, Hubert Metzner
-
Patent number: 7714107Abstract: The present invention relates to porous freeze-dried fibrin matrices substantially devoid of external anti-fibrinolytic agents, and methods of producing such matrices. Resilient matrices, also known as sponges, that are particularly beneficial for supporting three dimensional cell growth are obtained from plasma proteins substantially devoid of plasminogen or from partially purified plasma proteins, thus obviating the need for exogenous anti-fibrinolytic agents. Furthermore, incorporation of glycosaminoglycans and bioactive agents during the formation of the matrix results in a sponge having advantageous biological, mechanical and physical properties. The compositions of the present invention are useful clinically, without cells or as a cell bearing implants.Type: GrantFiled: July 26, 2005Date of Patent: May 11, 2010Assignee: ProChon Biotech Ltd.Inventors: Avner Yayon, Malkit Azachi, Micha Gladnikoff
-
Publication number: 20100113743Abstract: The present invention provides conjugates between Factor VII or Factor VIIa peptides and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action of a glycosyltransferase. The glycosyltransferase ligates a modified sugar moiety onto either an amino acid or glycosyl residue on the peptide. Also provided are pharmaceutical formulations including the conjugates. Methods for preparing the conjugates are also within the scope of the invention.Type: ApplicationFiled: October 23, 2009Publication date: May 6, 2010Applicant: Novo Nordisk A/SInventors: Shawn DeFrees, David A. Zopf, Susann Taudte, W. Scott Willett, Matthew Kalo, Robert J. Bayer
-
Publication number: 20100098703Abstract: The present invention provides methods for the isolation, identification, and purification of adrenomedullin (AM)-binding proteins. Also, provided are methods for utilizing the purified AM-binding proteins, or functional portions thereof, to diagnose, treat, and monitor AM-related diseases, for example, diseases or disorders associated with abnormally elevated AM levels. In addition, the present invention provides a newly identified complex between AM and a specific AM-binding protein 1 (AMBP-1); which has been isolated and identified herein as factor H (fH). The invention also provides AM/AMBP complexes, particularly AM/FH complexes, and antibodies specifically reactive with this complexes. Further provided are methods for identifying and purifying complexes of AM and an AM binding protein using anti-AM/fH antibodies, and methods for treating conditions such as cancer or diabetes utilizing compositions comprising these antibodies.Type: ApplicationFiled: December 15, 2009Publication date: April 22, 2010Inventors: Frank Cuttitta, Ted H. Elsasser, Alfredo Martinez, Rubén Pío
-
Patent number: 7700733Abstract: The present invention relates to novel polypeptide variants of factor VII (FVII) or factor VIIa (FVIIa) polypeptides, where said variants comprise an amino acid substitution in position 10 and 32 and where said variants further comprise a sugar moiety covalently attached to an introduced in vivo N-glycosylation site located outside the Gla domain. Such polypeptide variants are useful in therapy, in particular for the treatment of a variety of coagulation-related disorders, such as trauma.Type: GrantFiled: April 29, 2003Date of Patent: April 20, 2010Assignee: Bayer HealthCare LLCInventors: Jesper Mortensen Haaning, Kim Vilbour Andersen
-
Publication number: 20100093934Abstract: The present invention relates to a proteinaceous construct comprising a blood coagulation factor, e.g., Factor VIII (FVIII), being bound to at least one water soluble polymer, including a poly(alkylene oxide) such as polyethylene glycol (PEG). Further the present invention relates to methods of preparing PEGylated blood coagulation factor, e.g., FVIII, in the presence of bound antibodies. The invention also relates to methods for prolonging the in vivo-half-life of blood coagulation factor, e.g., FVIII, in the blood of a mammal having a bleeding disorder associated with functional defects or deficiencies of blood coagulation factor, e.g., FVIII.Type: ApplicationFiled: October 14, 2009Publication date: April 15, 2010Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: ARTUR MITTERER, MICHAEL GRANINGER, MEINHARD HASSLACHER
-
Patent number: 7696318Abstract: The present invention relates to methods and means for making Vitamin K-dependent protein compositions which are devoid or substantially devoid of protein contaminants. In particular, methods and means useful for the reduction or elimination of protein contaminants also being Vitamin K-dependent proteins are described.Type: GrantFiled: July 13, 2006Date of Patent: April 13, 2010Assignee: Novo Nordisk Health Care AGInventors: Thomas Dock Steenstrup, Peder Lisby Norby
-
Publication number: 20100087368Abstract: The present invention provides a method for preventing and/or treating subjects with acute renal failure caused by a variety of conditions. The method comprises administering to the subject soluble thrombomodulin which does not activate Protein C. In conjunction with standard of care, soluble thrombomodulin that does not activate Protein C will prevent or reduce acute kidney injury and subsequent morbidity and mortality.Type: ApplicationFiled: December 10, 2007Publication date: April 8, 2010Applicant: ELI LILLY AND COMPANYInventors: Brian William Grinnell, Bryan Edward Jones, Bruce A. Molitoris
-
Patent number: 7682808Abstract: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.Type: GrantFiled: February 23, 2006Date of Patent: March 23, 2010Assignee: The Board of Trustees of the University of IllinoisInventors: James H. Morrissey, Stephanie A. Smith, Roberto Docampo, Nicola J. Mutch
-
Publication number: 20100056428Abstract: Method of conjugating glycoproteins by means of chemical modification is provided as well as new modified glycoproteins.Type: ApplicationFiled: September 3, 2007Publication date: March 4, 2010Applicant: Novo Nordisk Health Care AGInventor: Carsten Behrens
-
Publication number: 20100048483Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: ApplicationFiled: August 21, 2009Publication date: February 25, 2010Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Guohan Yang, Ton T. Hai, Bennett Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Publication number: 20100047428Abstract: The invention is related to a process for extracting at least one protein present in milk, said protein exhibiting an affinity for the complexed or non-complexed calcium ions of said milk, comprising the following steps consisting of: a) releasing the protein by precipitation of calcium compounds obtained by contacting the milk with a soluble salt, the anion of which is selected for its capability to form said insoluble calcium compounds in such a medium, in order to obtain in this way a protein-enriched liquid phase, b) separating the protein-enriched liquid phase from the precipitate of calcium compounds, said liquid phase being, moreover, separated in a lipidic phase and in a non-lipidic aqueous phase comprising the protein, and c) recovering the non-lipidic aqueous phase comprising the protein.Type: ApplicationFiled: May 31, 2007Publication date: February 25, 2010Applicant: LFB BIOTECHNOLOGIESInventors: Alain Lejars, Michel Nogre, Michael Tellier
-
Publication number: 20100041872Abstract: The present invention provides conjugates between peptides and PEG moieties through glycerol linkers.Type: ApplicationFiled: October 4, 2007Publication date: February 18, 2010Inventors: Shawn DeFrees, Xiao Zeng
-
Publication number: 20100028372Abstract: An aqueous composition having increased protein stability is obtained by: a. determining a pH at which the protein has stability at the desired temperature; b. adding to the composition at least one displacement buffer wherein the displacement buffer has a pKa that is at least 1 unit greater or less than the pH of step (a); and c. adjusting the pH of the composition to the pH of step (a); wherein the aqueous composition does not comprise a conventional buffer at a concentration greater than about 2 mM and wherein the conventional buffer has a pKa that is within 1 unit of the pH of step (a).Type: ApplicationFiled: June 26, 2009Publication date: February 4, 2010Inventor: Jan Jezek
-
Publication number: 20100022755Abstract: A platelet aggregation inducing substance containing as an active ingredient a polypeptide having a peptide fragment represented by formula (1) (component A): -(Pro-X-Gly)n- ??(1) wherein X represents Pro or Hyp; and n represents an integer of from 20 to 5,000.Type: ApplicationFiled: December 12, 2007Publication date: January 28, 2010Applicant: CHISSO CORPORATIONInventors: Yasuto Umeda, Shinichi Takasaki, Takafumi Takebayashi, Takahiro Kawai
-
Patent number: 7645860Abstract: The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same.Type: GrantFiled: August 1, 2008Date of Patent: January 12, 2010Assignees: Baxter Healthcare S.A., Baxter International Inc.Inventors: Peter Turecek, Juergen Siekmann
-
Publication number: 20090318344Abstract: Methods for the treatment of coagulation disorders using Factor V/Va variants are provided.Type: ApplicationFiled: February 23, 2007Publication date: December 24, 2009Inventors: Rodney M. Camire, Valder R. Arruda
-
Patent number: 7618943Abstract: The present invention relates to fusion polypeptides, comprising at least two peptides. The invention further relates to the use of these fusion proteins in antivascular therapy of neoplastic diseases and to their use I the production of a drug for the treatment of neoplastic diseases.Type: GrantFiled: August 20, 2004Date of Patent: November 17, 2009Assignee: Oncoscience AGInventors: Wolfgang E. Berdel, Rolf M. Mesters
-
Publication number: 20090281283Abstract: The invention relates to a method for extracting a protein from milk, having at least one hydrophobic pocket and a negative charge to the natural pH of milk, that comprises the following steps: a) skimming and delipidation of the milk; b) passing the delipidated and skimmed fraction containing said protein on a chromatographic substrate on which is grafted a ligand having both a hydrophobic characteristic and a ionic characteristic in pH conditions enabling the protein to be retained on said substrate, the pH being higher than 4.6; c) elution of the protein; d) purification of the eluded fraction by removing the milk proteins from said eluded fraction; and e) recovering said protein.Type: ApplicationFiled: January 2, 2008Publication date: November 12, 2009Applicant: LFB BIOTECHNOLOGIES (SOCIETE PAR ACTIONS SIMPLIFIE UNIPERSONNELLE)Inventors: Alain Lejars, Michel Nogre, Monique Ollivier
-
Publication number: 20090281022Abstract: The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.Type: ApplicationFiled: July 15, 2009Publication date: November 12, 2009Applicant: Novo Nordisk HealthCare A/GInventors: HANS KURT PINGEL, Niels Kristian Klausen
-
Publication number: 20090258004Abstract: The invention is directed to blood proteins produced in monocot seeds and isolated therefrom for use in therapeutic compositions, and to methods of making these isolated blood proteins and to therapeutic compositions comprising them.Type: ApplicationFiled: November 27, 2007Publication date: October 15, 2009Inventors: Ning Huang, Raymond L. Rodriquez, Frank E. Hagie, David M. Stalker
-
Patent number: 7598352Abstract: A method of identifying a polypeptide monobody having target protein binding activity, said method comprising: providing a host cell comprising (i) a reporter gene under control of a 5? regulatory region operable in the host cell, (ii) a first chimeric gene which encodes a first fusion polypeptide comprising a target protein, or fragment thereof, fused to a C-terminus of a DNA-binding domain which binds to the 5? regulatory region of the reporter gene, and (iii) a second chimeric gene which encodes a second fusion polypeptide comprising a polypeptide monobody fused to a transcriptional activation domain; and detecting expression of the reporter gene, which indicates binding of the polypeptide monobody of the second fusion polypeptide to the target protein such that the transcriptional activation domain of the second fusion polypeptide is in sufficient proximity to the DNA-binding domain of the first fusion polypeptide to allow expression of the reporter gene.Type: GrantFiled: November 19, 2001Date of Patent: October 6, 2009Assignee: University of RochesterInventor: Shohei Koide
-
Patent number: 7598356Abstract: The present invention relates to a two-step method for isolating proteins from the cystine-knot superfamily based on dye ligand affinity chromatography and reversed-phase chromatography. Advantageously, the method can be performed in a relatively short period of time, involves inexpensive reagents, and requires little sample preparation before and during the purification process. Protein fusions between cystine-knot proteins and proteins of interest are further provided for the isolation of said protein of interest or complexes containing said protein of interest using the two-step method disclosed.Type: GrantFiled: July 8, 2004Date of Patent: October 6, 2009Assignee: Board of Regents of the University of Nebraska by and on Behalf of the University of Nebraska Medical CenterInventors: Elliott Bedows, Jason A. Wilken
-
Patent number: 7569665Abstract: The present invention relates generally to a molecular marker of the integrity of the extracellular matrix in an animal including a human subject. More particularly, the present invention provides a molecular marker of cartilage integrity. The identification of the molecular marker in circulatory or tissue fluid is indicative of disrepair of the extracellular matrix and in particular cartilage such as caused or facilitated by trauma or a degenerative disease or other condition, for example, arthritis or autoimmunity. The molecular marker is preferably in the form of a glycoprotein but the instant invention extends to genetic sequences encoding the polypeptide portion of the glycoprotein. Expression analysis of such genetic sequences provides predictive utility in detecting normal or abnormal extracellular matrix development.Type: GrantFiled: October 31, 2003Date of Patent: August 4, 2009Assignee: Murdoch Childrens Research Institute Royal Children's HospitalInventors: John Francis Bateman, David James Fitzgerald
-
Publication number: 20090176708Abstract: The present invention discloses a chemically modified FIX, wherein the activation peptide region contains a covalently coupled water-soluble hydrophilic polymer.Type: ApplicationFiled: December 19, 2008Publication date: July 9, 2009Inventors: Peter Turecek, Friedrich Scheiflinger
-
Publication number: 20090175828Abstract: The present invention relates to modified cDNA sequences coding for factor X polypeptides, in particular human factor X and its derivatives which can bypass the need for either factor VIIIa/factor IXa or factor VIIa/tissue factor for activation. The invention relates further to recombinant expression vectors containing such modified cDNA sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives which do have biological activities of the unmodified wild type protein but having altered activation properties, and processes for the manufacture of such recombinant proteins and their derivatives. The invention also covers a transfer vector for use in human gene therapy, which comprises such modified DNA sequences.Type: ApplicationFiled: February 19, 2007Publication date: July 9, 2009Inventors: Stefan Schulte, Hans-Peter Hauser, Uwe Kalina, Thomas Weimer
-
Publication number: 20090176967Abstract: New FVII polypeptides and FVIIa derivatives, uses of such peptides, and methods of producing these polypeptides and derivatives, are provided.Type: ApplicationFiled: August 2, 2005Publication date: July 9, 2009Applicant: Novo Nordisk HealthCare A/GInventor: Henning Ralf Stennicke
-
Publication number: 20090104121Abstract: Provided herein are methods and compositions for the in vitro formation of multi subunit biological platforms. The biological platforms may be used to screen chemical or biological compounds, in particular compounds that may disrupt or otherwise affect the formation of the multi subunit complexes, or disrupt already-formed in vitro assembled multi subunit complexes. Also provided herein are methods and compositions for the in vivo formation of multi-subunit biological complexes. The methods and compositions described herein may be used to develop animal models of diseases or disorders.Type: ApplicationFiled: September 29, 2008Publication date: April 23, 2009Applicant: Plaxgen, IncInventor: Shanmugavel Madasamy
-
Patent number: 7521210Abstract: The invention provides a method for large-scale production of a polypeptide, such as a Factor VII or Factor VIIa polypeptide, in eukaryote cells, such as mammalian cells, contained in a culture liquid, said method comprising: monitoring the concentration of dissolved CO2 in the culture liquid, and constantly or intermittently sparging atmospheric air through the culture liquid, wherein the sparging rate of the air is controlled in relation to the monitored concentration of dissolved CO2 in the culture liquid. The method reduces or eliminates the use of bases while providing an excellent pH control. The invention also provides a culture vessel suitable for the methods.Type: GrantFiled: March 30, 2006Date of Patent: April 21, 2009Assignee: Novo Nordisk Healthcare A/GInventor: Ida Mølgaard Knudsen
-
Publication number: 20090093616Abstract: The present invention is directed to a method for activation of Factor VII to FVIIa in solution.Type: ApplicationFiled: May 27, 2008Publication date: April 9, 2009Inventors: Claus M. Krebber, Sridhar Viswanathan
-
Publication number: 20090081218Abstract: A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.Type: ApplicationFiled: July 25, 2008Publication date: March 26, 2009Applicant: NOVAGEN HOLDING CORPORATIONInventors: Haitao WANG, Yong DU, Rui ZHANG, Jing XU, Longbin LIU
-
Publication number: 20090069543Abstract: The invention provides a method of treating bleeding disorders in a subject by administration of a preparation enriched for Factor IXa. The Factor IXa can be produced by proteolytically activating recombinantly-produced Factor IX. The invention also provides an improved method for producing Factor IXa from a plasma fraction, which method results in a Factor IXa product containing little or no prekallikrein activity, thus reducing the incidence of undesired side effects in a subject.Type: ApplicationFiled: July 30, 2008Publication date: March 12, 2009Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE SAInventors: Shane Donovan, Donald Baker
-
Patent number: 7501493Abstract: A method for preparing a stable dried composition of blood factor product containing a stabilizing amount of trehalose in the absence of a stabilizing amount of albumin is disclosed.Type: GrantFiled: August 20, 2007Date of Patent: March 10, 2009Assignee: Quadrant Drug Delivery LimitedInventor: Bruce Joseph Roser
-
Patent number: 7494971Abstract: The invention relates to a pharmaceutical active ingredient preparation for producing a medicament that contains thrombin or has a thrombin-generating capacity and compositions comprising thereof. The inventive preparation contains: (A) prothrombin obtained from plasma or by means of genetic engineering (coagulation factor II), (B) coagulation factors V, VIII, IX, X obtained from plasma or by means of genetic engineering, which can be at least partially in the activated state, and coagulation factor Xla obtained from plasma or by means of genetic engineering, and (C) phospholipids which are safe from prions and contribute to the clotting process, said phospholipids being optionally contained in liposomes.Type: GrantFiled: January 21, 2005Date of Patent: February 24, 2009Assignee: Bio & Bio Licensing SAInventor: Johann Eibl